罗格列酮治疗2型糖尿病疗效观察  

Efficacy of rosiglitazone on treating Type 2 diabetes

作　　者：郝齐志[1] 

机构地区：[1]商丘市第一人民医院内分泌科,商丘476100

出　　处：《郑州大学学报（医学版）》2005年第5期898-899,共2页Journal of Zhengzhou University(Medical Sciences)

摘　　要：目的:探讨罗格列酮治疗2型糖尿病的临床疗效和安全性。方法:2型糖尿病患者90例,按治疗前用药情况分为罗格列酮治疗组(R组),合用磺脲治疗组(B组),合用二甲双胍治疗组(A组),每组30例。R组先行饮食及运动治疗,A组及B组保持原药物剂量不变,然后3组均给予罗格列酮4mg,每d1次,空腹口服,共51周。治疗前后抽取患者静脉血,葡萄糖氧化酶法测空腹血糖(FBG)及餐后2h血糖(P2hBG);测糖化血红蛋白;放免法测空腹胰岛素(FINS);计算胰岛素敏感性指数(A)和胰岛素抵抗指数(R)。结果:治疗后3组患者FBG、P2hBG、糖化血红蛋白、FINS水平及R值均较治疗前下降,A升高。上述各指标治疗前后的变化3组间比较差异无统计学意义(P>0.05)。3组均未发生严重不良反应。结论:罗格列酮可单用或与二甲双胍、磺脲类合用,治疗2型糖尿病安全、有效。Aim ： To observe the efficacy of rosiglitazone on treating Type 2 diabetes. Methods： A total of 90 patients with Type 2 diabetes were allocated into 3 groups,30 in each group. Group R （which were treated with rosiglitazone） accepted diet control and had physical exercises,group A treated with sulfonylurea and group B treated with metformin before maintained the former administration. Then the 3 groups were all administrated rosiglitazone at a dose of 4 mg, 1 time per day for 51 weeks. Fasting blood glucose（FBG） , P2hBG, saccharification hemoglobin（HbAli） ,and fasting insuline（FINS） were determined before and after therapy, and resistance index（R） and sensitivity index（A） to insulin were calculated. Results ： FBG, P2hBG, HbAli, FINS, and R were decreased, and A was increased significantly in 3 groups of the pationts after treating with rosiglitazone. Conclusion： Rosiglitazone,or combined with sulfonylurea or metformin,is effective and safe in treatment of Type 2 diabetes.

关 键 词：罗格列酮 2型糖尿病 疗效 

分 类 号：R587.1[医药卫生—内分泌]